Evidence map›Paper›PMID 39783776›Full record

ArticleCancer medicine2025

FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival.

Nathalie B Rasko, Christopher B Nahm, John Turchini, Rachel Teh, Helge Rasmussen, Sooin Byeon, Sumit Sahni, Jaswinder S Samra, Anthony J Gill, Anubhav Mittal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Early cancer diagnosisWorld journal of gastrointestinal oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nathalie B RaskoFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Christopher B NahmFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
John TurchiniFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Rachel TehFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Helge RasmussenFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Sooin ByeonFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Sumit SahniFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-2900-8845
Jaswinder S SamraFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Anthony J GillFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Anubhav MittalFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFXYD3 is a Na/K-ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo-naive patients with surgically-resected PDAC at a single centre (1993-2014).

methodFXYD3 expression was assessed in tumour specimens using immunohistochemistry.

results145 of 180 PDAC tumour specimens were FXYD3-immunopositive (80.5%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log-rank p = 0.9718). FXYD3 expression correlated positively with late-stage disease (OR 3.041, 95% CI 1.190-7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade.

conclusionImmunohistochemical FXYD3 expression does not predict survival in chemo-naive PDAC patients, but is associated with late-stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmunohistochemistryMaleMembrane ProteinsMiddle AgedNeoplasm ProteinsNeoplasm StagingPrognosisBiomarkers, TumorFXYD3 protein, humanMembrane ProteinsNeoplasm ProteinsFXYD3MAT‐8pancreatic cancerpancreatic ductal adenocarcinomaprognosissurvival

Identifiers

PMID39783776
PMCPMC11714220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.